ClinicalTrials.gg
RecruitingNCT05885009HOPE-PROSTATEUpdated Aug 6, 2025

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

An observational study in Metastatic Prostate Cancer, sponsored by SOLTI Breast Cancer Research Group. Recruiting at 1 site in Spain. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by SOLTI Breast Cancer Research Group · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 312 studies in Prostatic Neoplasms with a site in Spain — 72 open to participants now, 126 under way, 45 of them phase 3. Prostatic Neoplasms · Spain.

Planned enrollment
35th of 51
240 · median 470
Started
2023
with 20 others
Observational
51 of 312
15 open now
Primary completion
2026-03
later than 35 of 125 live
Registered
239th of 312
by date

Among the 312 studies in Prostatic Neoplasms with a site in Spain, this one is the 35th largest by planned enrollment of the 51 observational ones that give a count, is one of 21 that started in 2023, is one of 51 observational ones, reaches primary completion later than 35 of the 125 other live ones, and was the 239th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

72 of the 312 studies in Prostatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Prostatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

HOPE Prostate is an observational study that aims at promoting research against metastatic prostate cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic prostate cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease, and to provide a blood sample and an archival tumor biopsy. In HOPE Prostate these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will try to enumerate future therapeutic options that match patient history and his genomic profile. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years.

The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic prostate cancer patients.

Read the detailed description

HOPE PROSTATE - SOLTI-2102 is a national, prospective, real-world clinical practice study for patients diagnosed with metastatic prostate cancer (mPC) who are about to receive, or receiving, or completed treatment for advanced disease under standard clinical practice conditions, regardless of where they are receiving their medical care (academics vs community practices).

Patients will lead their own inclusion and, participation, and self-provide follow-up data in the study through a digital tool that will guide them in every step of the journey. The digital tool will collect general patient characteristics and demographics data, informed consent, disease characteristics, diagnostic tools employed along their oncological history, sample collection dates (for tissue,blood and saliva), genetics and tumor mutations, treatment history, patient's expectations and perceptions with regards to the process of undergoing genomic tumor testing and clinical trial experience from patients living with mPC. Moreover, when patients involve their physicians, they will receive notifications from the platform with molecular reports and an invitation to participate in the periodic Molecular Advisory Boards of the study (MAB).

The study will be in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and applicable regulatory requirements. Approval of the study protocol will be from an Independent Ethics Committee (IEC).

Patients will request to participate in HOPE-PROSTATE through the study website and a personal session in the digital tool, will be created. Then:

  • In a short inclusion questionnaire patients will introduce some demographic and medical data, and if available, medical reports.
  • A medical monitor will validate that the inclusion and exclusion criteria are met and will contact patients to explain the study procedures, objectives and answer questions.
  • Upon validation, patients will be contacted through the digital tool to give their informed consent or alternatively in paper (at a partner local laboratory).
  • After informed consent validation, the digital tool will inform them of the steps to follow to proceed with their patient journey.
  • Patients will fill out a short questionnaire to assess their pre-test expectations with regards to anticipated implications of testing and motivations to undergo testing.
  • Before results obtention, patients will be required to complete a more extensive questionnaire about their medical history to use it at the Molecular Advisory Board (MAB) meeting.

An information letter will be sent to all patients to be forwarded to their treating physician to be aware of the HOPE-PROSTATE study objectives. Moreover, upon patient's consent, treating physicians will be invited to be registered in a database to be aware of testing progress, receive molecular results and participate in the periodic MAB.

Upon inclusion, patients will be instructed through the digital tool to attend the closest local partner laboratory to perform the necessary blood draw at an appropriate time. In addition, a letter to request the most recent tumor tissue sample at his hospital will be provided; we anticipate collecting tumor tissue samples from at least 80 included patients.

At partner local laboratory:

  • Patient may have the possibility to sign the paper study Informed Consent Form if digital signature is not possible.
  • Blood samples will be collected (at the time of disease progression).
  • Patients will hand over their tumor blocks, previously collected from the local hospitals. At the same time, a saliva sample will be collected.

At the time of documented disease progression and before the initiation of a subsequent line of therapy, patients will be instructed to contact SOLTI to organize their blood sample collection at the closest venue of the partner laboratory. The sample will be sent to the GuardantHealth central laboratory in Redwood City, California. A second blood sample from the same extraction will be shipped to the study central laboratory at Vall d'Hebron Institute of Oncology (VHIO) for complementary analyses.

While we anticipate most mPC patients would join the study in the castration-resistant setting, we plan for a subgroup analysis among patients who join the study at first diagnosis of metastatic, hormone-naïve disease. Patients with metastatic hormone-naïve disease will be included if the blood sample can be collected within 4 weeks from the start of luteinizing hormone releasing hormone antagonist (LHRHa) therapy, although ideally the sample should be collected even before LHRHa initiation. After enrolling 30 hormone-naïve disease patients, we will conduct a feasibility analysis based on the circulating tumor DNA (ctDNA) detection rate (considering an expected detection rate above 80%). If this approach is feasible, the subgroup of patients with metastatic hormone-naïve disease will continue to recruit up to a maximum of 100 patients.

Samples will undergo plasma-based Next Generation Sequencing panel using the "GuardantOMNI" panel test which is a diagnostic system based on the sequencing of 500 genes, as well as the determination of biomarkers that include microsatellite instability (MSI), tumoral mutational burden (TMB) and Homologous Recombination Deficiency (HRD) score. Molecular reports will be generated and sent to the patient physician (if involved), then these data will be discussed at the MAB and a MAB report with molecular data interpretation and a therapeutic recommendation (if there is any) will be send to the patient.

In certain populations of special interest, a repeated ctDNA analysis at a later timepoint will be considered after the MAB evaluation:

  • Patients with BRCA gene or HRD pathway alterations who have undergone the test before targeted treatment and develop secondary resistance to PARP inhibitors.
  • Patients who have undergone ctDNA prior to exposure to both docetaxel and androgen receptor-targeted agents (ARTA) (SoC Treatments) will be invited to be tested again after progression to these SoC agents to determine the possibility of discovering new therapeutic targets.

At least 80 tumor tissue samples from archival core biopsies or surgical specimens preferably metastatic will undergo genomic characterization. Samples will be sent by participating patients or through treating institutions upon patient's request.

Formaline-fixed paraffin embeeded (FFPE) blocks will be assessed at VHIO by a pathologist and H\&E slides will be digitalized. Samples with sufficient tumor content will undergo DNA extraction, quantification and quality control. The obtained DNA will be divided for two downstream applications:

  1. All samples will undergo targeted sequencing using a previously validated capture-based panel including >400 genes (mutations, Copy Number Alterations, TMB) at VHIO laboratories and a genomics report will be generated.
  2. For those samples with enough DNA quality and quantity after completing the study related targeted sequencing, remaining DNA will be used for retrospective whole exome or whole-genome sequencing (WGS) analysis using modified protocols optimized for FFPE samples for exploratory comparative analysis .

Patients will always have the possibility of getting their treating physician involved in their study participation at any point along the journey which will be recommend by the sponsor. Physicians will be invited to register in a database to inform them most efficiently. They will receive the molecular reports generated and will be invited to participate in the periodic MAB periodic meetings. When the patient case is presented, they will have the opportunity to do so. An informative letter will be provided to all patients so they can share it with their doctors at the time of inclusion.

Besides the study per se, HOPE PROSTATE-SOLTI-2102 educational program for Health Care Professionals (HCP) will focus on physicians treating mPC although their patients participate or not in the investigational part of the study. The two main educational initiatives will be: the Molecular Advisory Board (MAB) meetings and the Initial Educational Meeting.

Upon genomics data availability, patients will have the possibility to update their medical history record through a questionnaire in the platform. Using mPC patient clinical and molecular data a SOLTI dedicated team will prepare the periodic MAB meetings to discuss the cases with new genomics reports available to highlight the potential Scientific relevance of the molecular findings according to patient's clinical progression and discuss potential targeted therapies that could fit each of the cases. The MAB will complement the genomic reports with a text summarizing their interpretation of the results and if possible, the potential future therapeutic strategies that could be considered according to patient profile. We aim at generating a space where mPC HCP can learn about the emerging strategies in mPC management, how to interpret genomics data and embrace a fruitful debate to promote continuous learning about molecular alterations and training on how to use the newly available tools in the clinics. MAB meetings will be scheduled once or twice a month and when possible: they will be complemented with brief educational lectures addressing relevant hot topics in PC management.

Three months after the MAB final report is sent, patients would fill out a second questionnaire to notify if the information received was relevant for subsequent treatment decisions. Moreover, they will be required to fill out the questionnaire to assess the fulfillment of their previous expectations.

This Board will be constituted by a multidisciplinary group of experts in PC clinical management (including medical oncologists, urologists and radiation oncologist), cancer genetics, cancer genomics, bioethics, and pathology. The board aims to be representative of the diversity in our country for managing prostate cancer patients. Besides permanent MAB members, physicians treating HOPE PROSTATE study participants will be invited to participate in the discussions about their patients. Moreover, SOLTI will disseminate the MAB meetings, allowing the free attendance of interested HCP from across the nation. With the aim of promoting participation among nation-wide physicians, these meeting will be held in Spanish and using an online platform.

Irrespective of the MAB outcome, all patients' clinical evolutions will be followed. Patients will be asked to self-report follow-up data every 6 months to determine the status of their disease through the digital tool for at least three years.

To reaffirm the patients-centric approach of HOPE PROSTATE-SOLTI-2102, the study will be complemented by a patient empowerment program that will include informative digital video-capsules and video tutorials about precision medicine and the HOPE Prostate project itself. The content from the digital workshop sessions will be available online and the videos will be public and accessible through the study website to facilitate access to information.

Understanding the patient experience is key to deliver patient-centered care. By looking at various aspects of the patient experience (expectations, concerns, attitudes, and knowledge), we aim at improving healthcare respecting the individual patient's preferences, needs and values.

Before pursuing the genomic test, patients will be invited to complete a series of questionnaires (adapted from previous studies), focused on patients' knowledge about genomic testing and their concerns and expectations around how genomic testing may impact the treatment selection and disease managements9. Three months after MAB report delivery, the same questionnaires will be repeated to evaluate the fulfillment of their previous expectations and the overall experience of the patient participating in the study. After this initial post-recommendation questionnaire, shorter follow up questionnaires will be displayed every six months for three years.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • molecular advisory board
  • molecular tumor board
  • genomic data
  • targeted therapy
  • patient-centric trials
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male patients diagnosed with metastatic prostate cancer living and being treated in Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male patients living in Spain.
  2. Age ≥18 years.
  3. Signed before any screening procedure.
  4. PC of any subtype confirmed both pathologically and radiologically (stage IV disease).
  5. The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any in either a clinical trial or the standard of care healthcare setting.
  6. (ECOG) 0-1.

Exclusion criteria

Exclusion Criteria:

  1. Inability to consent or conform to the processes involved in a clinical study.
  2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • GeneticLiquid Biopsy

    Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy

  • GeneticArchival Tumor DNA sequencing

    Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis

06

What researchers measure

Primary outcomes

  1. To evaluate the feasibility of a liquid-biopsy based Comprehensive Genomic Panel (CGP) test in the management of mPC patients, following a patient-centric approach

    Percentage of patients for whom a liquid biopsy result can be obtained.

    Time frame: Ongoing basis during 5 years of study duration

  2. To evaluate the impact of a liquid-biopsy based CGP test in the management of mPC patients, following a patient-centric approach

    Proportion of patients with a putatively targetable (ESCAT levels I-III) alteration detected.

    Time frame: Ongoing basis during 5 years of study duration

Secondary outcomes

  1. To describe the genomic landscape of mPC in a real-world population beyond clinical trials using validated targeted sequencing assays in tissue and ctDNA.

    Frequency of PC gene mutations in the study population including DNA repair pathways (BRC1/2 inactivating mutations, etc.), genes associated with phosphatidylinositol-3 kinase (PI3K) and cell cycle regulation pathways and others.

    Time frame: Ongoing basis during 5 years of study duration

  2. To study the feasibility of liquid-biopsy based genomic testing in patient subsets: metastatic hormone-naïve and castration-resistant mPC

    ctDNA detection rate in hormone-naïve and castration-resistant mPC.

    Time frame: Ongoing basis during 5 years of study duration

  3. To study the concordance rate for key genomic alterations between ctDNA and tumor targeted sequencing (in a subset of patients who have both samples available).

    * Concordance between ctDNA mutation status and tissue mutation status (specially in Homologous Recombination Repair and other clinically relevant genes). * Concordance between ctDNA and tissue TMB calculations. * Concordance between ctDNA and tissue Variant Allelle Frequency for given mutations.

    Time frame: Ongoing basis during 5 years of study duration

  4. To study the clinical impact of genomic testing in terms of matched therapies prescribed from treating physicians.

    Percentage of patients who received a matched therapy against an alteration detected by ctDNA and/or tissue targeted sequencing during the follow-up period.

    Time frame: Ongoing basis during 5 years of study duration

  5. Description Overall Survival (OS) among the included patients

    Describe OS from the moment of registration to the death of the patient.

    Time frame: Ongoing basis during 5 years of study duration

  6. Description Progression Free Survival (PFS) of treatments aimed at identified alterations

    Describe PFS with treatments directed to molecular targets identified in ctDNA.

    Time frame: Ongoing basis during 5 years of study duration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2026, 36 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 36 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
Jun 1, 2023
StartActual
Mar 28, 2023
Primary completionEst.
Mar 28, 2026
CompletionEst.
Mar 28, 2028
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05885009
Lead sponsor
SOLTI Breast Cancer Research Group
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Mar 28, 2023
Primary completion
Mar 28, 2026 (estimated)
Completion
Mar 28, 2028 (estimated)
Last update
Aug 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion